Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
Do you utilize tumor treating fields in patients with anaplastic Pleomorphic Xanthoastrocytoma PXA III?
Related Questions
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
Is there a role for intravenous temozolomide in place of oral for the 5-day dosing q 28 days after surgery/XRT+Temozolomide for glioblastoma multiforme?
When is the best time to try targeted therapy in adult-type diffuse non-IDH glioma?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?
In what circumstances would you consider use of IDH inhibitors in high-grade astrocytomas?
What approach do you use when treating adult diffuse gliomas with H3-G34 mutations, now classified into their own category under the 2021 glioma guidelines?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
How do you approach anti-seizure medication management when it was started by another team for a seizure-naive patient before/after craniotomy for a tumor?
